Evidence map›Paper›PMID 26138095›Full record

ArticleBMC medical genetics2015

The role of p19 and p21 H-Ras proteins and mutants in miRNA expression in cancer and a Costello syndrome cell model.

Roseli García-Cruz, Maria Camats, George A Calin, Chang-Gong Liu, Stefano Volinia, Cristian Taccioli, Carlo M Croce, Montse Bach-Elias

Open access · goldAbstract read
In one paragraph

Article in BMC medical genetics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. The RNA-binding proteins hnRNP H and F regulate splicing of a MYC-dependent HRAS exon in prostate cancer cells.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  3. Article
  4. Review
  5. Article
  6. ANGPTL1 attenuates colorectal cancer metastasis by up-regulating microRNA-138.Journal of experimental & clinical cancer research : CR · 2017
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Roseli García-CruzInstituto de Investigaciones Biomédicas de Barcelona- CSIC, C/ Egipcíacas15, 08001, Barcelona, Spain. roseli_760901@hotmail.com.
Maria CamatsInstituto de Investigaciones Biomédicas de Barcelona- CSIC, C/ Egipcíacas15, 08001, Barcelona, Spain. marie19es@gmail.com.
George A CalinOhio State University, Department of Molecular Immunology, Virology and Molecular Genetics, Columbus, Ohio, 43210, USA. george.calin@osumc.edu.
Chang-Gong LiuOhio State University, Department of Molecular Immunology, Virology and Molecular Genetics, Columbus, Ohio, 43210, USA. chang-gong.liu@osumc.edu.
Stefano VoliniaOhio State University, Department of Molecular Immunology, Virology and Molecular Genetics, Columbus, Ohio, 43210, USA. s.volinia@gmail.com.
Cristian TaccioliOhio State University, Department of Molecular Immunology, Virology and Molecular Genetics, Columbus, Ohio, 43210, USA. Cristian.Taccioli@osumc.edu.
Carlo M CroceOhio State University, Department of Molecular Immunology, Virology and Molecular Genetics, Columbus, Ohio, 43210, USA. croce.5@osumc.edu.
Montse Bach-EliasInstituto de Investigaciones Biomédicas de Barcelona- CSIC, C/ Egipcíacas15, 08001, Barcelona, Spain. montse.bach@iibb.csic.es.
The Ohio State University · USInstitut d'Investigacions Biomèdiques de Barcelona · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundP19 H-Ras, a second product derived from the H-Ras gene by alternative splicing, induces a G1/S phase delay, thereby maintaining cells in a reversible quiescence state. When P21 H-Ras is mutated in tumour cells, the alternative protein P19 H-Ras is also mutated. The H-Ras mutation Q61L is frequently detected in different tumours, which acts as constitutive activator of Ras functions and is considered to be a strong activating mutant. Additionally, a rare congenital disorder named Costello Syndrome, is described as a H-Ras disorder in children, mainly due to mutation G12S in p19 and p21 H-Ras proteins, which is present in 90 % of the Costello Syndrome patients. Our aim is to better understand the role of p19 and p21 H-Ras proteins in the cancer and Costello Syndrome development, concerning the miRNAs expression.

methodsTotal miRNAs expression regulated by H-Ras proteins were first analyzed in human miRNA microarrays assays. Previously selected miRNAs, were further analyzed in developed cell lines containing H-Ras protein mutants, that included the G12S Costello Syndrome mutant, with PCR Real-Time Taq Man miRNA Assays primers.

resultsThis study describes how p19 affects the RNA world and shows that: i) miR-342, miR-206, miR-330, miR-138 and miR-99b are upregulated by p19 but not by p19W164A mutant; ii) anti-miR-206 can restore the G2 phase in the presence of p19; iii) p19 and p21Q61L regulate their own alternative splicing; iv) miR-206 and miR-138 are differentially regulated by p19 and p21 H-Ras and v) P19G12S Costello mutants show a clear upregulation of miR-374, miR-126, miR-342, miR-330, miR-335 and let-7.

conclusionsThese results allow us to conclude that the H-Ras G12S mutation plays an important role in miRNA expression and open up a new line of study to understand the consequences of this mutation on Costello syndrome. Furthermore, they suggest that oncogenes may have a sufficiently important impact on miRNA expression to promote the development of numerous cancers.

Indexed as

AnimalsCells, CulturedCell Transformation, NeoplasticCostello SyndromeEmbryo, MammalianGene Expression Regulation, NeoplasticHeLa CellsHumansMiceMicroRNAsModels, BiologicalMutant ProteinsNeoplasmsProtein IsoformsProto-Oncogene Proteins p21(ras)ras ProteinsMicroRNAsMutant ProteinsProtein IsoformsProto-Oncogene Proteins p21(ras)ras Proteins

Identifiers

PMID26138095
PMCPMC4631104
OpenAlexW1800737473

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.